A hypercoagulable and hypofibrinolytic state is detectable by global methods in patients with retinal vein occlusion

详细信息    查看全文

• 作者：Anna Paola Cellai ; Donatella Lami ; S ; ra Fedi ; Rossella Marcucci ; Lucia Mannini ; Caterina Cenci ; Angela Rogolino ; Andrea Sodi ; Ugo Menchini ; Rosanna Abbate ; Domenico Prisco
• 关键词：Clot lysis time ; Endogenous thrombin potential ; Retinal vein occlusion ; Tissue factor pathway inhibitor
• 刊名：Atherosclerosis
• 出版年：2012
• 出版时间：September, 2012
• 年：2012
• 卷：224
• 期：1
• 页码：97-101
• 全文大小：240 K

文摘

The pathogenesis of retinal vein occlusion (RVO), has not been well understood. Recent data have shown the efficacy of an anticoagulant therapy with LMWHs in the treatment of acute RVO suggesting the presence of a hypercoagulable state in these patients. New global tests for detection of hypercoagulability and hypofibrinolysis have become available and their application might improve the knowledge of the pathophysiology of RVO and, potentially, its treatment. The aim of our study was to evaluate coagulation and fibrinolytic alterations by two global tests in RVO patients: Endogenous Thrombin Potential (ETP) and Clot Lysis Time (CLT), respectively. We studied 81 RVO patients (40 males; median age 61 years) and a control group matched for age and sex. The ETP was measured by functional chromogenic assay and expressed as the time until thrombin burst (LagTime), Time to peak (T_max), Peak amount of thrombin generation (C_max) and ETP. CLT was determined by a plasma-based, tissue factor-induced clot lysis assay. C_max, ETP and CLT values were significantly higher in RVO patients than in controls (C_max p?=?0.010; ETP p?<?0.001; CLT p?<?0.001) and remained significantly associated with the disease at the multivariate analysis adjusted for cardiovascular risk factors. Our results indicate that -beyond the assay of different parameters associated with clotting activation and lysis- global methods might allow us to easily detect the presence of hypercoagulability and hypofibrinolysis in RVO patients. Further studies should assess the possible clinical value of our data in the management of RVO patients.